-
Who we are
Who we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
What we do
What we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Blog
Blog
Novavax is committed to accelerating the development of new and promising vaccines and sharing information based on years of study and experience.
Investor Hub
Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.
Latest quarterly earnings
Latest investor presentation
Latest clinical presentation
Latest publications
Annual report
NASDAQ:NVAX
Our ESG Approach
Discover the steps we have taken in the areas of access, governance, environment, and diversity and find our latest sustainability reports.
Why invest with us
We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.
Over my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges and I firmly believe in the platform that we use to manufacture our recombinant protein. Our technology is key as we continue to respond to challenges posed by the SARS-CoV-2 endemic and other vaccine-preventable infectious diseases.
Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine
Get notifications for investor updates
Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.
Investor inquiries
Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at [email protected]
Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.